knowledge -WSS

knowledge

author：comprehensive 2025-10-02 00:51:43 - browse：44673

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, at a hearing — policy coverage from STAT — Peter Marks, director of the FDA's Center for Biologics Evaluation and Research Greg Nash/Pool via AP

WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff to emerging pathogens, after the FDA scrambled to find people for Covid-19 priorities like Operation Warp Speed.

“Vaccines were a pretty heavy duty lift during the pandemic,” said Peter Marks, director of the Center for Biologics Evaluation and Research, at a Thursday Politico event. “Rather than having to essentially reassign whole groups of people and disrupt things, the idea is to have a group of people who are constantly working on this.”

There is reason for optimism. Sens. John Hickenlooper (D-Colo.) and Ted Budd (R-N.C.) successfully added an amendment creating that team to a key pandemic preparedness bill that must be reauthorized by the end of September. It would establish this new program within Marks’ division of the FDA, staffed with experts on vaccines, antibodies, diagnostic tests, personal protective equipment, and other medical countermeasures. Among other activities, this team would enhance surveillance programs and prioritize vaccine research and development so that existing platforms can be retooled to fight other viruses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Pushing for an NIH office for post

focus

WSS

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

John Green on his newest strategy for fighting tuberculosis

FDA advisers back CAR

First U.S. drug developed to treat liver disease MASH is approved

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

How many hemophilia patients actually want gene therapy?

hotspot

knowledge

focus

How one medical school became remarkably diverse

Covid’s new normal has set in amid another rise in cases

Cancer drug shortages should be causing more outrage

RaDonda Vaught links Vanderbilt hospital issues to patient death

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Ebola: Gilead Sciences antiviral shows promise as new treatment

Drug repurposing or repositioning? The language matters

FDA advisers back CAR

ChatGPT in medicine: STAT answers readers' burning questions

EPA limits use of carcinogenic gas for sterilizing medical devices

leisure time

People with substance use disorder deserve online privacy

Information blocking fines are now fair game in health care

WuXi out of biotech trade group, U.S. and China relations to blame

First U.S. drug developed to treat liver disease MASH is approved

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Pushing for an NIH office for post

hotspot

focus

focus

entertainment